LivaNova heads into its July 29 earnings date with short sellers quietly adding pressure after a strong month for the stock.
The most notable tension this week is the divergence between price and positioning. LIVN gained 4.5% on the week and 11.4% over the past month, closing at $82.23. Yet short interest climbed alongside that rally — up 6.5% week-on-week to 6.6% of free float, the highest level in the 30-day window. That combination, shorts building into a rising stock, is the defining setup heading into late July.
Positioning in the lending market tells a more nuanced story. Borrow remains cheap and plentiful. Availability is running at 559% — meaning there are roughly 5.5 shares available to borrow for every one already shorted — well above the 52-week floor of 461%. Cost to borrow is a negligible 0.46%. Neither metric signals a crowded or stressed short book; the shorts are accumulating but doing so with ease. Options confirm the absence of strong directional conviction. The put/call ratio is 0.55, just marginally above its 20-day average of 0.53, with a z-score below 1. There is no elevated demand for downside protection in the options market, which sits in contrast to the directional short-interest move.
The Street is modestly constructive but divided on upside. Freedom Capital Markets initiated coverage this week with a Hold and an $81 target — roughly in line with the current price. That follows Keybanc raising its target to $92 (from $83) with an Overweight rating on June 22. The consensus mean target sits near $81.45, essentially flat to where LIVN is trading today, which limits the implied upside from analyst estimates. The bull case centers on management's 2025 revenue guidance of $940–955 million — strong mid-teens growth from 2024's $803 million — plus potential market-share gains from the aura6000 neuromodulation device. Bears flag the risk that growth decelerates sharply to low-single digits beyond 2025, with margin compression and lingering FDA uncertainty on the aura6000. The PE is running near 18x, EV/EBITDA at 11.6x — neither extreme, but the factor profile is uninspiring: EPS surprise ranks in just the 25th percentile and the analyst recommendation score sits at the 5th percentile, reflecting how narrowly covered and cautiously rated this name is.
Among closely correlated peers this week, ICUI rose 8.2% and TCMD gained 12.6%, both outperforming LIVN's 4.5% move. IART gave back 4.2% on Tuesday alone, and BAX added 6.1%. The mixed read across health-care equipment names suggests LIVN's week was more stock-specific than sector-driven — which makes the simultaneous short build more pointed.
One element worth watching alongside the July 29 print is the insider activity from mid-June. Several directors and a chief-level officer sold shares on June 15 at prices around $79.70–$80.19, on the same day a cluster of equity awards was granted. Net insider activity over 90 days is nominally positive — roughly 25,000 shares and $1.7 million — but that net figure is almost entirely driven by the awards rather than open-market purchases. The sells were small in dollar terms, all below $100,000, and trade significance scores were rated at just 1–2 out of 10. The pattern looks routine rather than a signal of concern.
The July 29 Q2 report is the next hard test. The most recent comparable print in May produced a 23% single-day gain — a reaction large enough that how management frames full-year guidance and aura6000 progress will be watched closely, and whether the current short build proves timely or exposed.
See the live data behind this article on ORTEX.
Open LIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
